Fig. 8

Combined treatment of Panc-1/PSC subcutaneous xenografts. a Scheme of combination therapy. The pancreatic tumour-bearing mice received Au@PP/RA/siHSP47 intravenously every 2 days for three injections and subsequently received gemcitabine intravenously every 2 days for five injections. b Body weight changes of mice during treatment. The data are shown as the mean ± s.d. (n = 5). c Tumour growth curves during treatment. The data are shown as the mean ± s.d. (n = 5). The mean tumour volumes were analysed using the Mann–Whitney U test. ^**p < 0.01, ^***p < 0.001. d Image of excised tumours. e Tumour weights after treatment. The data are shown as the mean ± s.d. (n = 5). ^**p < 0.01, ^***p < 0.001 (Student’s t test). f Histological studies with H&E and immunohistochemical staining of proliferating cell nuclear antigen (PCNA) in tumour sections. Scale bars, 50 μm. g Quantification of PCNA-positive tumour cells. The data are shown as the mean ± s.d. (n = 5). ^**p < 0.01, ^***p < 0.001 (Student’s t test)